News
FBRX
0.5571
-2.42%
-0.0138
Weekly Report: what happened at FBRX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at FBRX last week (0708-0712)?
Weekly Report · 07/15 10:59
Weekly Report: what happened at FBRX last week (0701-0705)?
Weekly Report · 07/08 11:01
Weekly Report: what happened at FBRX last week (0624-0628)?
Weekly Report · 07/01 11:01
Weekly Report: what happened at FBRX last week (0617-0621)?
Weekly Report · 06/24 11:08
Weekly Report: what happened at FBRX last week (0610-0614)?
Weekly Report · 06/17 11:00
CAMAC FUND LP - FORTE BIOSCIENCES' BOARD WILL BE EXPANDED TO NINE SEATS, ONE INCUMBENT DIRECTOR WILL RESIGN, TWO DIRECTORS SELECTED BY CAMAC FUND
Reuters · 06/17 10:30
CAMAC FUND LP SAYS ON JUNE 11, ENTERED INTO SETTLEMENT AGREEMENT WITH FORTE BIOSCIENCES - SEC FILING
Reuters · 06/17 10:30
CAMAC FUND LP SAYS ON PURSUANT TO SETTLEMENT AGREEMENT FORTE BIOSCIENCES WILL FORM COMMITTEE OF BOARD TO EXPLORE STRATEGIC ALTERNATIVES
Reuters · 06/17 10:30
Weekly Report: what happened at FBRX last week (0603-0607)?
Weekly Report · 06/10 11:02
Weekly Report: what happened at FBRX last week (0527-0531)?
Weekly Report · 06/03 11:05
Forte Biosciences Initiated at Buy by Brookline Capital
Dow Jones · 05/30 10:06
Forte Biosciences Price Target Announced at $4.00/Share by Brookline Capital
Dow Jones · 05/30 10:06
Brookline Capital Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $4
Benzinga · 05/30 09:56
Weekly Report: what happened at FBRX last week (0520-0524)?
Weekly Report · 05/27 11:09
Weekly Report: what happened at FBRX last week (0513-0517)?
Weekly Report · 05/20 11:03
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. Is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The company announced the issuance of equity inducement awards to new non-executive employees. The Company is advancing its product candidate, FB102.
Barchart · 05/17 15:05
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)
TipRanks · 05/14 12:02
FBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024
Forte Biosciences reported earnings per share of -16 cents for the first quarter of 2024. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports. Forte B biosciences just reported results for first quarter 2024.
Investorplace · 05/14 01:54
Forte Biosciences, Inc. Quarterly Report: Condensed Consolidated Financial Statements and Management's Discussion and Analysis
Press release · 05/13 22:56
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.